Vertex Pharmaceuticals (NASDAQ: VRTX) is proof that Wall Street doesn't always reward companies with monopolies. It markets the only approved drugs that treat the underlying cause of cystic fibrosis (CF), but the company's shares have fallen 30% from the highs set in 2020.
The big drugmaker announced its first-quarter results after the market closed Thursday. However, the update didn't move the needle much, with the biotech stock moving less than 1% higher in after-hours trading. Here are the highlights of Vertex's Q1 update.
Image source: Getty Images.
For further details see:
Here's How Vertex Pharmaceuticals Beat Expectations in Q1